The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly has followed through on its ... study in 643 patients showed no impact of the drug on scales used to monitor cognition in Alzheimer's patents overall, although Cortexyme maintains ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Many Alzheimer’s experts were dismayed — but ... Three others received consulting fees from Eli Lilly, Biogen, and Eisai, among other drug makers active in the AD field. One author is a ...

Antimicrobials, vaccines, and anti-inflammatories are associated with a reduced risk for Alzheimer disease and dementia.

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Eli Lilly and Company (NYSE ... as well as people with the mild dementia stage of Alzheimer's disease who have confirmed amyloid pathology.1,2 The Egyptian Drug Authority approved the insulin ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) revealed long-term study results indicating that over 80% of adults and adolescents with moderate-to-severe atopic dermatitis... ByInvesting ...